hotspot -WSS

hotspot

author：leisure time 2025-10-02 17:21:11 - browse：69

Slayman with (left to right) Dr. Leo Riella, Medical Director of Kidney Transplantation, Dr. Nahel Elias, Interim Chief, Division of Transplant Surgery, his partner, Faren, and Dr. Tatsuo Kawai, Director, Legorreta Center for Clinical Transplant Tolerance. -- HEALTH coverage from STAT — Rick Slayman, holding hands with his partner, Faren, poses with members of his Massachusetts General Hospital medical team before being going home last month. Michelle Rose/Massachusetts General Hospital

Rick Slayman, the first man to receive a kidney transplant from a genetically engineered pig, has died, according to a statement from his family and Massachusetts General Hospital, where he underwent the historic operation in March.

“Our family is deeply saddened about the sudden passing of our beloved Rick but take great comfort knowing he inspired so many,” his family said in the statement released Saturday evening.

The hospital did not say how or when Slayman died. A spokesperson declined to provide further information, citing “privacy issues.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Elizabeth Holmes banned from government health programs

WSS

Readout Newsletter: Merck, J&J, and long Covid

Dewpoint Therapeutics lays off staff after losing partnerships

Biohaven protein

Latest bird flu infection made farmworker sicker than earlier cases

Insmed lung disease drug hits target in key Phase 3 trial

My yearlong odyssey to get my son’s ADHD medication covered

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Virginia high school admissions case could be legal follow

Report: NIH

Psychedelics group wrestles with new pharma identity

Report: NIH

Tori Bowie and the unacceptable rates of Black maternal death

Do more moles mean more problems? Not so, says new study

Trump demands the U.S. pay no more for drugs than other countries … again

First Opinion Podcast: What happens when kids become caregivers?

At least 13 dead in Texas as scorching temps continue

NIH director takes cautious approach to Biden drug pricing priority

leisure time

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Prior authorization will have to move faster under new Biden rule

Why doctors need education on FDA device approval process

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

iTeos Therapeutics debuts first data on TIGIT

knowledge

leisure time

explore

focus